Stock Market Reviews

ENVB (Enveric Biosciences, Inc.) News

Get the latest news, insights, and market updates on ENVB (Enveric Biosciences, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Enveric Biosciences Announces Withdrawal of Petition Against Its Patent
  CAMBRIDGE, Mass., February 25, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the previously announced Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals (Gilgamesh) against Enveric’s issued U.S. Patent No. 12,138,276 (the ’276 patent) has been withdrawn. This action follows Enveric’s filing of a Requ
  Feb 25, 2026 - $ENVB
• Weekly Roundup on the Cannabis Sector & Psychedelic Sector
  Key Takeaways; Cannabis Sector Organigram Secured C$65.2 Million Strategic Investment from British American Tobacco After the Company Agreed to Acquire Sanity Group Canopy Growth Secured Shareholder Backing for MTL Cannabis Acquisition Green Thumb Expanded Credit Facility with Additional $50 Million Key Takeaways; Psychedelic Sector Enveric Reported New EB‑003 Data Highlighting Non-Hallucinogenic Neuroplastogen Strategy Compass Pathways […]
  Feb 23, 2026 - $ENVB
• Enveric Biosciences reports EB-003 receptor engagement assay data
  Enveric Biosciences (ENVB) announced new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and ss-arrestin-mediated signaling downstream of the 5-HT2A receptor. Multiple independent, peer-reviewed studies have previously shown that selective activation of 5-HT2A receptor, by either Gq-biased or ss-arrestin-biased agonists, can independently produce antidepressant- and anxiolytic-like effects in preclinical models, suggesting that therapeutic benefit can arise fro
  Feb 20, 2026 - $ENVB
• Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data
  CAMBRIDGE, Mass., February 19, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT₂A receptor. Multiple independent, peer-reviewed studies have previously shown that selective activatio
  Feb 19, 2026 - $ENVB
• Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option
  CAMBRIDGE, Mass., January 29, 2026--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that its subsidiary, Akos Biosciences, has licensed to TOTEC Pharma, Inc. ("TOTEC") its US Trademark portfolio for RCANN™ and an RCANN™ design. TOTEC, an affiliate of Aries Science & Technology ("Aries"), is advancing the commercialization o
  Jan 29, 2026 - $ENVB
• Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
  CAMBRIDGE, Mass., January 28, 2026--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 328,802 shares of common stock at a purchase price of $4.41 per share. In a concurrent private placement, t
  Jan 28, 2026 - $ENVB
• Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
  CAMBRIDGE, Mass., January 28, 2026--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it has entered into definitive agreements for the purchase and sale of 328,802 shares of common stock at a purchase price of $4.41 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private
  Jan 28, 2026 - $ENVB
• Enveric Biosciences announces issuance of U.S. patent
  Enveric Biosciences (ENVB) announced the issuance of U.S. Patent No. 12,492,179 entitled, “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives” with claims to compositions and methods of treatment for novel molecules with the potential to be developed for mental health disorders. The ‘179 patent expands the protection of Enveric’s pipeline of potentially neuroplastogenic and non-hallucinogenic molecules. Claim 70% Off TipRanks This Holiday SeasonUnlock hedge fund-level data and power
  Dec 30, 2025 - $ENVB
• Enveric Biosciences Announces Patent Issuance
  CAMBRIDGE, Mass., December 29, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the issuance of U.S. Patent No. 12,492,179 entitled, "Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives" (the "‘179 patent"), with claims to compositions and methods of treatment for novel molecules with the potential to be develope
  Dec 29, 2025 - $ENVB
• Weekly Roundup on the Cannabis Sector & Psychedelic Sector
  Key Takeaways; Cannabis Sector Cronos Acquired Europe’s Largest Adult-use Cannabis Company Aurora Introduced a New Proprietary Cultivar to Polish Market Trulieve Redeemed Costly 2026 Senior Secured Notes and Lined Up Fresh $100M Financing Key Takeaways; Psychedelic Sector Enveric Strengthened Mental Health Drug Pipeline with a New Patent Milestone PharmAla Marked Key Manufacturing Milestone with Australian-Made […]
  Dec 15, 2025 - $ENVB